Navigation Links
Lilly Declares Fourth-Quarter 2013 Dividend
Date:10/21/2013

INDIANAPOLIS, Oct. 21, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2013 of $0.49 per share on outstanding common stock.

The dividend is payable December 10, 2013 to shareholders of record at the close of business on November 15, 2013.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  F-LLY

Refer to: (317) 276-5795 Mark Taylor

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
2. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
3. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
4. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
5. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
6. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
7. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
8. Dr. Marschall S. Runge Elected to Lilly Board of Directors
9. Lilly Reports Second-Quarter 2013 Results
10. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
11. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
(Date:5/2/2017)... and NEW YORK ... As the leading distributor of market intelligence, ... European Med Tech Reimbursement Consulting AB that ... Tech Reimbursement Consulting AB,s proprietary market analyses through the ... professionals around the world easy access to complete product ...
Breaking Medicine Technology:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... North Carolina have remained steady since 2009, according to a Workers Compensation Research ... The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and a 2017 Best in KLAS category winner, has named Daniel P. Bullington ... extend and enhance its technology platform and product offerings,” says Justin Neece, president. ...
(Date:5/23/2017)... ... , ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner ... Speaker and Contributor to a weeklong series of classes, meetings, field trips and special ... Walter Schindler and SAIL Capital have received an increasing number of ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due to months of ... call for diligence, asking homeowners to scout for any open water sources that can ... the annoying buzz of mosquitos is the buzz associated with potential infections stemming from ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech For Solutions has announced ... laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology ... MedTech Group Purchasing vendor , will provide specialized equipment to ensure OvaTools participants ...
Breaking Medicine News(10 mins):